PT  - JOURNAL ARTICLE
AU  - Alexander, Lori
ED  - Ridker, Paul
TI  - Rosuvastatin Reduces Primary Cardiovascular Events in Apparently Healthy Individuals with Elevated C-Reactive Protein Levels
DP  - 2009 Feb 01
TA  - MD Conference Express
PG  - 12--13
VI  - 8
IP  - 8
4099  - http://mdc.sagepub.com/content/8/8/12.short
4100  - http://mdc.sagepub.com/content/8/8/12.full
AB  - This large prospective study is the first to show that statin therapy can prevent cardiovascular (CV) events among individuals who do not have elevated lipid levels. The Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin [JUPITER; NCT00239681] trial demonstrated that rosuvastatin 20 mg significantly reduced the rate of primary CV events in an apparently healthy population that had normal low-density lipoprotein levels but elevated high-sensitivity C-reactive protein levels.